Clinical Trial Update: Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rivastigmine for mild cognitive impairment has been terminated. The update discusses the trial's efficacy and safety findings up to t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: Novartis | Conditions: Cognitive Symptoms | Phase 3 | Status: TERMINATED